Wikipedia is a free, multilingual, web-based, and openly editable encyclopedia maintained by a global community of volunteers. It’s hosted by the non-profit Wikimedia Foundation. Wikipedia offers articles on various topics, ranging from celebrities and science to history and culture. It’s considered one of the…
Definition and diagnostic criteria of clinical obesityRubino, Francesco et al.The Lancet Diabetes & Endocrinology, Volume 13, Issue 3, 221 – 262 The Lancet Diabetes & Endocrinology Commission’s comprehensive work on defining and diagnosing clinical obesity, distinguishing it from mere excess adiposity. A large…
Clinical trials are carefully designed research studies conducted in humans to evaluate the safety, efficacy, and overall benefit of medical interventions such as drugs, biologics, or devices. They progress through phases 1 to 4, each with distinct goals, methods, and…
Enforcement discretion means that a regulatory agency like the FDA (U.S. Food and Drug Administration) chooses not to enforce certain rules or regulations under specific circumstances, even if technically a violation has occurred. This is often done:• To avoid disrupting…
Abdul-Rahman T, Roy P, Ahmed FK, Mueller-Gomez JL, Sarkar S, Garg N, Femi-Lawal VO, Wireko AA, Thaalibi HI, Hashmi MU, Dzebu AS, Banimusa SB, Sood A. The power of three: Retatrutide’s role in modern obesity and diabetes therapy. Eur J…
Chen H, Liu S, Gao S, Shi H, Yan Y, Xu Y, Fang J, Wang W, Chen H, Liu Z. Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System. Sci…
Drug delivery for incretins refers to how medications that mimic or enhance the activity of incretin hormones—primarily GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)—are formulated and administered to achieve optimal therapeutic effect. These drugs are primarily used in type…
by William A Seeds MD (Author) ($36.00) In The Quantum Power of GLP-1 Peptides: Unlocking the Science that Leads to Lasting Weight Loss and Optimal Healthspan, Dr. William A.Seeds uncovers the cellular mechanisms behind GLP-1s and other peptides that can help people lose significant…
This academic article, “Nutritional priorities to support GLP‐1 therapy for obesity,” is a joint advisory from several prominent American health organizations. It examines the use of GLP-1 receptor agonists (GLP-1s) for obesity treatment, highlighting their efficacy in weight reduction and other clinical benefits while also addressing…
PharmaVoice article discusses the Trump administration’s decision not to expand Medicare and Medicaid coverage for GLP-1 obesity drugs, despite their increasing use and the potential for significant market growth for companies like Eli Lilly and Novo Nordisk. Although a Biden-era proposal…